A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
← catalyst calendarSponsored by Toray Industries, Inc (industry) · 3402.T — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
138actual
Sites
14
Countries
France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-26 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2019-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor
- Colorectal Cancer
- Cholangiocarcinoma
- Bladder Cancer
- Ovarian Cancer
- Gastric Cancer
- Palpable Subcutaneous Malignant Lesions
- Renal Cell Carcinoma
- Melanoma
- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
Interventions
- Biological: TRK-950
- Biological: TRK-950
- Biological: TRK-950
- Drug: Irinotecan
- Drug: Leucovorin
- Drug: 5-FU
- Drug: Gemcitabine
- Drug: Cisplatin
- Drug: Carboplatin
- Drug: Ramucirumab
- Drug: Paclitaxel
- Drug: Nivolumab
- Drug: Pembrolizumab
- Drug: Imiquimod Cream
- Drug: Bevacizumab
- Drug: PLD
Primary outcomes
what the primary-completion date above is the date OFFrequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0
measured through study completion, an average of 1 year
Frequency of patients experiencing adverse events of special interest (AESIs)
measured through study completion, an average of 1 year
Blood pressure
measured through study completion, an average of 1 year
Heart rate
measured through study completion, an average of 1 year
Respiratory rate
measured through study completion, an average of 1 year
Temperature
measured through study completion, an average of 1 year
Weight
measured through study completion, an average of 1 year
Height
measured through study completion, an average of 1 year
Performance status using Karnofsky performance status criteria
measured through study completion, an average of 1 year
QTc interval determined from 12-lead Electrocardiogram
measured through study completion, an average of 1 year
QRS interval determined from 12-lead Electrocardiogram
measured through study completion, an average of 1 year
Frequency of patients with laboratory abnormalities (Complete Blood Count, Coagulation, Urinalysis and Serum Chemistry)
measured through study completion, an average of 1 year
Publications
- PMID 37082579 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 3402.T's whole pipeline · Catalyst calendar · Every registered study · What changed